Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
Cost-effectiveness of a Functional and Respiratory Rehabilitation Intervention in Patients Who Receive an Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
The objective of the study is to evaluate the benefits and costs of a comprehensive rehabilitation program (physical, psychological, social and educational) for patients receiving hematopoietic stem cell transplantation (HSCT). It is a prospective longitudinal study with a control group. Patients will be included who will perform a transplant in the hospital environment. The variables of the study will be: number and type of complications, days of hospitalization, readmissions, economic cost of the program, exercise tolerance, assessment of muscular atrophy, health related quality of life, knowledge and self-management of the disease, all of them adjusted for the variables age, sex and hematological disease, as well as comorbidities. The evaluations will be performed before transplantation (between one and three months before), during the conditioning phase (intensive chemotherapy), before discharge, after immediate discharge and after discharge up to one year. The nursing team will perform the patient's therapeutic education, stimulation for physical activity, as well as evaluation and follow-up measures. Early detection of the needs of the rest of the rehabilitation team will be carried out. There will be a support function for the physiotherapist in regard to physical activity. In Spain there is no interdisciplinary team that provides comprehensive care and rehabilitation to this type of patients and few studies are dedicated to rehabilitation beyond physiotherapy as a preventive tool for future disabilities.
Working hypothesis
- 1. Patients who receive a Hematopoietic Stem Cell Transplantation (HSCT) who follow a
comprehensive rehabilitation program, have fewer post-transplant complications, reduce
the number of hospital stay days, and return to their daily lives more quickly.
- 2. The economic costs derived from the incorporation of the rehabilitation program will
be lower than the savings caused by the decrease in complications, hospital stay and
consumption of health resources.
Goals
Main objectives
- To evaluate the quality of life related to health in the hematological patient who has
received a HSCT and on which a new preventive functional rehabilitation intervention
(other than physiotherapy) is applied.
- To compare the number and type of respiratory and other complications after HSCT among
the intervention group compared to a control group.
- Estimate the effects of the rehabilitation program on tolerance to exercise in the
short, medium and long term, as well as detect the change in lifestyle if this occurred.
Secondary objectives
- Evaluate and compare the days of hospital stay and the time elapsed in each of the
specialized units (insulation, Intensive Care Unit, single room with High Efficiency
Particulate Air, (HEPA filter).
- To qualify the economic costs of the physiotherapy intervention within the
rehabilitation program, the complications and the days of hospitalization.
- To evaluate the incidence of muscular atrophy and the level of tolerance to the effort
as indicative of physical deconditioning and sedentary lifestyle.
- Measure the amount of symptoms, or the frequency of them: pain (measured by visual
analog scale for pain (VAS), nausea / vomiting, insomnia, anxiety, anorexia ...)
Methodology
This is a prospective experimental study with a control group prior to the start of the
intervention, which will include 190 participants. The sample size was calculated using a 95%
confidence level and considering a positive and negative variability of 50% since there are
no previous studies applying this methodology and taking into account the high mortality
associated with the infection that oscillates between 35 and 50% according to the studies.
The subjects will be treated in the hospital setting in airtight rooms with HEPA filters.
Patients will be collected correlatively from the moment they enter the transplant program
and sign informed consent. The control group will be collected retrospectively, from the day
1 of the startup of the program to 75, after verifying that they do not meet any inclusion
criteria. Recruitment and incorporation into the study will be continuous according to the
appearance of cases that meet the inclusion criteria.
The study will include patients receiving HSCT for the next 2 years from the study start date
and will be followed and evaluated for a period of one year after transplantation.
Outcomes:
Quality of life, post-transplant complications, especially respiratory, capacity for exercise
tolerance, muscular atrophy, onset of sleep disorders, days of stay in different hospital
units, cost of interventions: physiotherapy, treatment of complications, and program
rehabilitation. Mortality related to the transplantation, which covers any lethal
complication from the moment of conditioning and without intervening the patient's underlying
disease, that is, the progression of the same. Assess adherence to the program and evaluation
and knowledge acquired by the patient.
Measurements:
To make the measurements, use:
- Bioimpedance analysis body composition (BIA), (Quantum X, RJL-Systems instruments™, Mi,
USA): This test is performed on the patients in the intervention group at baseline, at
discharge from hospital for transplantation, at the month of discharge, and at 3, 6, and
12 months, in order to assess their body composition, their fat mass and their muscle
mass.
- Six-minute-walk test (to complement the assessment of exercise tolerance): This test is
performed on the patients in the intervention group at baseline, at discharge from
hospital for transplantation, at the month of discharge, and at 3, 6, and 12 months, in
order to assess the exercise tolerance described in meters traveled, percentage of
normality, symptomatology (dyspnea / fatigue of legs), and heart rate recovery. The
abrupt weight changes in this population will be decisive for the interpretation of
these data.
- Muscle strength test (handgrip (Jamar™ Dynamometer, Preston, Jackson, Mi, USA) and 1RM):
This test is performed on the patients in the intervention group at baseline, at
discharge from hospital for transplantation, at the month of discharge, and at 3, 6, and
12 months, in order to assess the strength in upper limbs at different times of process.
- Functional Assessment of Cancer Therapy questionnaires (FACT) validated in Spanish, to
measure quality of life associated with the disease (lymphoma (LYM), leukemia (LEU),
multiple myeloma (MM), Bone marrow transplantation (BMT); fatigue, anorexia): This test
is performed on the patients in the intervention group at baseline, at discharge from
hospital for transplantation, at the month of discharge, and at 3, 6, and 12 months in
order to evaluate subjectively different aspects of health: functional, physical,
emotional, as well as other concerns and symptoms associated with the process.
- Physical activity questionnaire for adult subjects -Modified Baecke Questionnaire™- (to
measure the sedentary lifestyle): This test is performed on the patients in the
intervention group at baseline, at discharge from the transplant hospital, at the month
of discharge, and at 3, 6, and 12 months, in order to subjectively assess physical
activity which subjects can develop during the first year of the transplant, and if
there are limitations due to complications or readmissions.
- Anxiety-depression assessment (HAD) questionnaire. This test is performed on patients in
the intervention group at baseline, at discharge from the transplant hospital, at the
month of discharge, and at 3, 6, and 12 months, in order to assess the role of anxiety
and depression at different times of the transplant and its follow-up in one year.
- Pittsburgh Sleep Quality Index. This test is performed on the patients in the
intervention group at baseline, at discharge from the transplant hospital, at the month
of discharge, and at 3, 6, and 12 months, in order to assess the subjective quality of
sleep in these patients during the transplant period and their follow-up for one year.
It is intended to evaluate the previous present difficulties, the use of hypnotics or
other drugs used, and the need for continuity of treatments, as well as the
effectiveness of them. The quality of sleep in hospitalized patients is highly
documented, but it is not present in this type of patients nor is there any longitudinal
follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00766883 -
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
| Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
| Completed |
NCT02564458 -
Fitness in Allogeneic Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
| Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
| Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
| Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
| Recruiting |
NCT04937634 -
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT04203108 -
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
|
Phase 4 | |
| Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
| Withdrawn |
NCT03279133 -
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
|
Phase 4 | |
| Completed |
NCT05151406 -
Myths and Misconceptions About HSCT in a Limited Resource Region
|
N/A | |
| Completed |
NCT02241005 -
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
|
N/A | |
| Recruiting |
NCT03689465 -
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
|
Phase 4 | |
| Recruiting |
NCT04868786 -
Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT03010579 -
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
|
Phase 4 |